Herpes, HPV, Hep B: What You Need to Know About STD Vaccines

Published: July 2025 | Last updated: May 2026

The short answer to "are there STD vaccines?" is yes, for three specific infections, plus active research on several more. HPV, hepatitis B, and hepatitis A all have safe, well-studied shots that prevent infections linked to cancers, chronic liver disease, and acute hepatitis outbreaks. For herpes, HIV, chlamydia, gonorrhea, syphilis, and trichomoniasis, there is no licensed vaccine yet, though candidates are moving through trials. This article covers what each existing vaccine actually does, who is eligible at what age, where the research stands in 2026, and how vaccines fit alongside testing as a real prevention plan.

This article is published by stdrapidtestkits.com, which sells at-home STI testing kits. We recommend products based on fit for the reader's concern, not commercial benefit. Vaccination decisions belong with your clinician; this article is a summary of current public-health guidance, not personal medical advice.

Why some STDs have vaccines and others don't

Vaccine development is not a question of effort. It is a question of how the immune system responds to a specific pathogen. Vaccines work best against viruses or bacteria that cause a clear, durable antibody response after natural infection. HPV, hepatitis B, and hepatitis A all fit that profile. The body learns them, the vaccine teaches the same lesson safely, and protection holds for years.

The other major STIs are harder targets. HIV mutates rapidly and integrates into the host's own DNA. Herpes simplex hides inside nerve cells, where antibodies cannot easily reach it, and reactivates from there. Chlamydia lives inside human cells, complicating the immune response. Gonorrhea has shown a striking ability to dodge antibodies and resist antibiotics. Syphilis remains poorly understood at the immune level despite being known for centuries. Trichomoniasis is a parasite, not a bacterium or virus, and parasitic vaccines are a separate scientific problem with no commercial candidate close to approval.

The three approved STD vaccines at a glance

Each of these has decades (or, for HPV, nearly two decades) of post-licensure data showing strong real-world effectiveness. Each is recommended by the CDC's Advisory Committee on Immunization Practices (ACIP) for specific age groups, and most are covered by U.S. insurance under the Affordable Care Act's preventive-services benefit.

HPV: the cancer-prevention vaccine

Human papillomavirus (HPV) is the most common sexually transmitted infection in the world. It spreads through skin-to-skin genital contact and often causes no symptoms at all. Most infections clear on their own, but persistent high-risk strains can lead to cervical, anal, throat, vulvar, vaginal, and penile cancers, plus genital warts.

The current vaccine is Gardasil 9, which targets nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58). According to the CDC's HPV vaccine information, HPV vaccine has the potential to prevent more than 90% of cancers caused by HPV. Per the WHO HPV and cervical cancer fact sheet, types 16 and 18 together cause approximately 76% of cervical cancers worldwide, and most anogenital warts are caused by types 6 or 11. The CDC Pink Book chapter on HPV documents the same strain attributions in U.S. surveillance data and confirms that more than 90% of anogenital warts trace to types 6 or 11. The benefit is largest when the series is given before exposure to the targeted strains.

Recommendations from the Advisory Committee on Immunization Practices (ACIP):

• Routine vaccination for everyone at ages 11 to 12 (can start as early as age 9).
• Catch-up vaccination through age 26 for anyone not previously vaccinated.
• Shared clinical decision-making for adults aged 27 through 45 who were not previously vaccinated. The benefit is smaller in this group because more people have been exposed already, but vaccination still protects against strains a person has not yet encountered.

One persistent gap: the vaccine is for everyone, not only girls. Boys, men, and people of any gender who have sex benefit from HPV vaccination because they can develop HPV-related cancers (oropharyngeal cancer in men is rising) and because vaccination reduces transmission to partners.

One thing to know even if you are fully vaccinated: cervical cancer screening (Pap or HPV DNA test) still applies on the schedule your clinician recommends. Gardasil 9 covers the highest-risk strains, but not every cancer-causing type.

HPV vaccine has the potential to prevent more than 90% of cancers caused by HPV.

Hepatitis B: the vaccine many adults already have

The hepatitis B vaccine has been around since 1981 and has been part of routine childhood immunization in the U.S. since 1991. Similar programs run in many other countries. If you were vaccinated as a child, you may already be protected. According to the WHO hepatitis B fact sheet, the vaccine offers nearly 100% protection against the virus, giving long-term defense against acute and chronic infection. The CDC hepatitis B vaccination page echoes the same general guidance for U.S. readers and lays out the routine schedule.

Hepatitis B is a virus that attacks the liver. Acute infection can cause fatigue, abdominal pain, nausea, dark urine, and jaundice. In some adults the infection becomes chronic, raising the risk of cirrhosis, liver failure, and liver cancer over decades. The virus spreads through blood, semen, and vaginal fluids, which makes sex a real transmission route alongside shared needles and perinatal exposure.

The current ACIP recommendation, updated in 2022, is universal hepatitis B vaccination for all adults aged 19 through 59 who are not already immune. Adults 60 and older are vaccinated based on risk factors (multiple partners, healthcare work, people who inject drugs, people living with HIV or chronic liver disease, household contacts of someone with chronic hepatitis B).

The standard schedule is three doses over six months. A newer 2-dose adult option called Heplisav-B is also available and reaches protective immunity faster. Routine boosters are not recommended for healthy adults who completed the primary series; protection appears to last decades, possibly lifelong. Twinrix is a combined hepatitis A and B vaccine given as a 3-dose series, which is convenient if you need both.

If you don't know your status, a simple blood test (anti-HBs antibody titer) can confirm immunity. The NHS hepatitis B information covers the same ground for readers in the UK.

Hepatitis B Rapid Home Test

Hepatitis B At-Home Rapid Self-Test Kit

$59.00

Fingerstick blood test for hepatitis B surface antigen. Useful if you have potential exposure, want to confirm chronic carrier status, or are deciding whether to start vaccination. Result in about 15 minutes at home.

Test for Hepatitis B

Hepatitis A: the STD vaccine that does not get sex-positive attention

Hepatitis A rarely shows up in sexual-health conversations, but it should. The virus spreads through the fecal-oral route, which includes oral-anal sexual contact and any scenario where microscopic amounts of fecal material transfer between partners. The CDC has documented hepatitis A outbreaks among men who have sex with men since the 1990s, including multi-state outbreaks from 2016 to 2018.

Unlike hepatitis B, hepatitis A does not become chronic. The acute illness can be severe, though. It causes sudden fever, fatigue, nausea, jaundice, dark urine, and abdominal pain. Most people recover in weeks. A small fraction (older adults, people with chronic liver disease) develop fulminant liver failure.

The hepatitis A vaccine is a 2-dose series (0 and 6 to 12 months). The CDC hepatitis A vaccination page describes both types of hepatitis A vaccine as safe and highly effective, and recommends completing the full series for long-term protection. Protective antibody levels have been shown to persist for many years in published follow-up studies, with some data suggesting decades of durability. Current CDC guidance prioritizes:

• All children at age 1.
• Men who have sex with men.
• People with chronic liver disease or HIV.
• People using or injecting drugs.
• People experiencing homelessness.
• International travelers to regions with elevated hepatitis A circulation.

If your sexual practices include oral-anal contact, you fall into the recommended group whether or not you fit the MSM category. A clinician can confirm whether you were vaccinated as a child (some states added hep A to routine childhood schedules in the late 1990s and 2000s) or whether you should catch up.

Herpes: no approved vaccine, but research is active

There is no licensed vaccine for herpes simplex (HSV-1 or HSV-2). The reasons are biological. Herpes establishes lifelong latency in nerve cells, which sit in immune-privileged tissue where antibodies are less effective. The virus reactivates periodically, and a vaccine has to either prevent that latency or reduce its consequences enough to be worth the effort.

Genital herpes is common. The CDC's genital herpes page reports an estimated 572,000 new genital herpes infections in the U.S. among people aged 14 to 49 in 2018, on top of an even larger pool of existing infections. Globally, the WHO herpes simplex virus fact sheet estimates about two-thirds of the world's population under age 50 carries HSV-1 and roughly 13% of people aged 15 to 49 carry HSV-2. Many people never have symptoms, or have such mild symptoms that they go unrecognized.

Both types spread through skin-to-skin contact, not just intercourse. Kissing transmits HSV-1. Oral-genital contact transmits either type to the genital area. The virus can also be shed (and transmitted) without visible sores, which is why condoms reduce risk substantially but do not eliminate it.

Research candidates as of 2026 include:

• mRNA-1608 (Moderna): an mRNA-based preventive HSV-2 vaccine in early-phase trials since 2023.
• BNT163 (BioNTech): an mRNA preventive HSV-2 candidate using a platform similar to its COVID-19 vaccines, also in Phase 1.
• HSV529 (NIH): a replication-defective live vaccine that completed Phase 1 with modest immune responses; further development is currently inactive.
• Therapeutic vaccines: aimed at people already infected, with the goal of reducing outbreak frequency and viral shedding. Several Phase 2 candidates; none approved.

None of these are close to FDA approval. Phase 1 and 2 trials test safety and immune response. Phase 3 trials, which test real-world prevention, take years to enroll and follow patients. Until that work finishes, herpes management relies on antiviral medication (acyclovir, valacyclovir, famciclovir).

HIV: real progress, no licensed vaccine yet

An HIV vaccine has been called the holy grail of immunology for decades, with good reason. HIV mutates so quickly that any single antibody target tends to become obsolete by the time the immune system mounts a strong response. The virus also integrates into the host's DNA, hiding inside the very immune cells a vaccine tries to mobilize.

Forty years of research have produced multiple high-profile trial failures: HVTN 702 in 2020, the Mosaico trial in 2023, and Moderna's mRNA-1644 multi-step regimen, developed with IAVI to target broadly neutralizing antibodies, which was discontinued in 2024 after early disappointing data. As of 2026, no HIV vaccine is in late-stage trials with strong efficacy data. Several mRNA-based and protein-based candidates remain in Phase 1, including BG505 SOSIP-based native-like Env trimer immunogens designed to elicit broadly neutralizing antibodies. VRC01 and other broadly neutralizing antibodies (bNAbs) are also being studied as infused monoclonal antibodies rather than active vaccines, with mixed Phase 2 results so far.

What works now, and works very well:

• PrEP (pre-exposure prophylaxis): daily oral pills (Truvada or Descovy) or long-acting injectable cabotegravir (Apretude) every two months. The CDC's PrEP information describes PrEP as reducing the risk of getting HIV from sex by about 99% when taken as prescribed, with maximum protection reached after roughly 7 to 21 days depending on exposure type.
• PEP (post-exposure prophylaxis): a 28-day course of antiretrovirals started within 72 hours of a possible exposure.
• Condoms and regular testing: still essential for anyone with multiple or new partners. A rapid at-home HIV antibody test gives results in about 15 minutes from a fingerstick blood drop. Per the CDC HIV testing page, antibody tests (including most rapid and self-tests) can usually detect HIV 23 to 90 days after exposure, while an antigen/antibody lab test from a vein can usually detect HIV 18 to 45 days after exposure.
• U=U (undetectable equals untransmittable): people living with HIV who are on effective treatment with an undetectable viral load do not transmit the virus to sexual partners.

Chlamydia, gonorrhea, syphilis, and trichomoniasis: why no shots yet

These four are common, often asymptomatic, and (for the bacterial three) curable with antibiotics. So why no vaccine? The challenge is immune evasion. Each of these pathogens has developed ways to slip past the immune system, which means natural infection rarely produces strong, lasting immunity. A vaccine has to do better than the body does on its own, and that is harder than it sounds.

• Chlamydia: the most reported bacterial STI in the U.S. and globally. Roughly 1.6 million U.S. cases were reported in 2022 per CDC national STI surveillance reporting, with true incidence almost certainly higher because most infections are silent. Untreated chlamydia can scar the fallopian tubes and cause infertility or ectopic pregnancy. Pelvic inflammatory disease from undetected infections drives that scarring, and the damage accumulates silently across repeat infections in roughly one in ten to one in seven untreated cases. Because most chlamydia infections produce no symptoms at all, routine annual screening is the only reliable way to catch it before the damage happens. The University of Southampton's prototype vaccine moved into early-phase human trials in the early 2020s. Realistic timeline to approval is years, not months.
• Gonorrhea: highly antibiotic-resistant strains are spreading globally, and the WHO ranks drug-resistant Neisseria gonorrhoeae as a top-priority pathogen. Observational studies have suggested that a meningitis B vaccine (Bexsero, 4CMenB) provides partial cross-protection, because the two bacteria share surface proteins. CDC is studying off-label use; ACIP has not issued a gonorrhea-specific recommendation. Dedicated gonorrhea vaccine candidates are in early development.
• Syphilis: the bacterium Treponema pallidum is genuinely strange and difficult to grow in the lab, which has slowed vaccine work for decades. Syphilis cases are rising sharply in the U.S., with congenital syphilis (mother to baby) rising fastest, but no candidate is close to approval. Treatment with penicillin is highly effective when caught early; late-stage syphilis causes irreversible neurological and cardiovascular damage.
• Trichomoniasis: a parasitic infection, often asymptomatic in men but causing itching, discharge, and discomfort in women. No vaccine in development. Treatable with metronidazole.

Because three of these infections are curable, the practical answer is regular testing. The CDC recommends annual chlamydia and gonorrhea screening for sexually active women under 25 and for older women with risk factors. At least annual screening is recommended for sexually active men who have sex with men, with syphilis testing on the same schedule.

One scope note on our home-testing kits: our at-home rapid kit for trichomoniasis is validated for vaginal self-swab only. Male readers who suspect trichomoniasis should see a clinic. Our HPV at-home test is similarly validated for women only. Our chlamydia, gonorrhea, HIV, syphilis, and hepatitis kits are validated for any gender.

Are you too old for an STD vaccine?

The short answer is usually no, especially for hepatitis B and hepatitis A. The longer answer depends on which vaccine.

• HPV: FDA-approved through age 45. ACIP recommends routine catch-up vaccination through age 26 and shared clinical decision-making between ages 27 and 45. Adults in that older window often benefit less than younger people because more strains have already been encountered, but the vaccine still protects against strains the person has not yet been exposed to. The decision is worth a real conversation with a clinician, not an automatic "you're too old."
• Hepatitis B: ACIP now recommends universal hepatitis B vaccination for all adults aged 19 through 59 who are not already immune. Older adults with risk factors (multiple partners, healthcare work, certain medical conditions) are also recommended. There is no upper age cutoff for protection.
• Hepatitis A: no upper age cutoff. If you fall into a CDC at-risk group (MSM, chronic liver disease, HIV, certain travel) and have not been vaccinated, you are still eligible.

If a primary care provider dismisses an adult vaccination question without checking immunization records or discussing your risk profile, that is reasonable grounds for a second opinion. Adult vaccination is a normal part of care, not an unusual ask.

What's in the vaccine pipeline for 2026 and beyond

Sexual-health research has accelerated since the global push on mRNA platforms during COVID-19. The table below lists the most-watched candidates as of 2026, with the realistic phase and timeline for each. None of these are over-the-counter close. Even if a candidate clears Phase 3 with strong efficacy, FDA approval, manufacturing scale-up, and ACIP recommendations add years. As of 2026, HPV, hepatitis B, and hepatitis A vaccination remain the only licensed STD vaccines, and that is unlikely to change in the very near term. See ClinicalTrials.gov for current trial listings.

Vaccine myths worth retiring

The internet still circulates a few persistent claims about STD vaccines that don't hold up.

Myth: STD vaccines are only for women. The HPV, hepatitis B, and hepatitis A vaccines are recommended for all genders. HPV-related cancers occur in men (oropharyngeal, anal, penile) and rates of oropharyngeal cancer in men have been rising for years. Vaccination protects the recipient and reduces transmission to partners.

Myth: if you're already sexually active, it's too late. Vaccines still protect against strains you have not yet been exposed to. The benefit is largest before any exposure, but vaccination after the start of sexual activity is not pointless. The ACIP shared decision-making window through age 45 reflects this.

Myth: hepatitis B is only a needle-sharing concern. Hepatitis B spreads through semen, vaginal fluids, and blood. Sexual transmission is well-documented. The current ACIP recommendation is universal adult vaccination through age 59, regardless of named risk factors.

Myth: hepatitis A is a food-poisoning issue, not an STD issue. It is both. Foodborne transmission and oral-anal sexual contact are both established routes. The CDC has tracked MSM-associated hepatitis A outbreaks for three decades.

Myth: there is a herpes vaccine but pharmaceutical companies are hiding it. No. Several candidates have failed in trials over the last 20 years, most notably Genocea's GEN-003, halted in 2017 after Phase 2 efficacy data fell short, and earlier candidates from GSK and others. The current trials are publicly registered on ClinicalTrials.gov. That kind of slow attrition is typical for high-difficulty biology targets, not evidence of suppression.

Myth: vaccinated means protected from all STDs. The HPV, hepatitis B, and hepatitis A vaccines protect against those three specific viruses only. They do not affect risk of herpes, HIV, chlamydia, gonorrhea, syphilis, or trichomoniasis.

Chlamydia, Gonorrhea & Syphilis 3-in-1 Rapid Test

3-in-1 Chlamydia, Gonorrhea & Syphilis Rapid Test Kit

$177.00

Self-collected swab plus fingerstick blood test that screens for the three bacterial STIs that currently have no vaccine. Results in about 15 minutes at home. A practical option for routine screening when you're sexually active with new or multiple partners.

Screen for Chlamydia, Gonorrhea, and Syphilis

The "I'm vaccinated, I'm covered" trap

One of the most consequential misunderstandings in sexual health is assuming that childhood or adult vaccination provides general STI protection. It does not. The hepatitis B series prevents hepatitis B. The hepatitis A series prevents hepatitis A. The HPV series prevents the HPV strains it targets. None of these vaccines have any effect on chlamydia, gonorrhea, syphilis, herpes, HIV, or trichomoniasis.

This matters because false confidence delays testing. Someone who believes they are "covered" may skip screening, dismiss symptoms, or assume a new partner's vaccination history covers them too. The bacterial STIs in particular often present with no symptoms at all and quietly cause damage (pelvic inflammatory disease, infertility, ectopic pregnancy risk) before they are discovered.

Vaccines are powerful for the specific infections they target. Routine testing, condom use, knowing your partner's status, and PrEP for those at higher HIV risk fill the gap.

Vaccines + testing: the realistic two-part strategy

Testing and vaccination serve different purposes and neither substitutes for the other. The HPV, hepatitis A, and hepatitis B vaccines remove those infections from your risk profile, often permanently. Testing catches the STIs we cannot yet vaccinate against, ideally before they cause complications and before they're transmitted to partners.

If you're unsure where to start, a multi-infection rapid kit covers the most common bacterial and viral STIs in one box. For a specific concern (a recent unknown-status partner, a possible HIV exposure, a sore that won't heal), a single-infection rapid test gives a faster answer. For symptoms that genuinely concern you, see a licensed clinician; an at-home test cannot replace a physical exam.

How to ask your doctor about STD vaccines

The conversation does not have to be awkward. A few practical scripts:

• "Can you check my immunization records for HPV, hepatitis B, and hepatitis A?"
• "If I haven't had them, am I eligible? I'm in my [age range]."
• "I've started dating again and want to be proactive about prevention. What does that look like for someone my age?"
• "What's the catch-up schedule for HPV if I'm starting late?"
• "My antibody status for hepatitis B is unknown; can we test before deciding on the series?"

Bottom line

Three STD vaccines exist, work well, and are widely available: Gardasil 9 for HPV, the hepatitis B series, and the hepatitis A series. All three are recommended for all genders and all three have age windows that extend well beyond adolescence. For herpes, HIV, chlamydia, gonorrhea, syphilis, and trichomoniasis, no licensed vaccine exists yet, though research is active on several. Until those candidates clear trials and reach the clinic, the gap is filled by routine testing, condoms, PrEP for those at higher HIV risk, and honest conversations with partners. If you don't know your vaccination status, an antibody check or a look at your immunization records is a reasonable first step.

1. U.S. Centers for Disease Control and Prevention. HPV vaccine information for clinicians and patients, including the >90% cancer-prevention figure and ACIP recommendations.
2. U.S. Centers for Disease Control and Prevention, Pink Book Chapter 11: Human Papillomavirus. Strain-attribution data showing types 6 and 11 cause more than 90% of anogenital warts.
3. World Health Organization. Hepatitis B fact sheet: source for the 'nearly 100% protection against the virus' framing and global transmission/epidemiology context.
4. U.S. Centers for Disease Control and Prevention. Hepatitis B vaccination page: schedule, the 2022 universal-adult recommendation, and general safety/effectiveness framing.
5. U.S. Centers for Disease Control and Prevention. Hepatitis A vaccination page: 2-dose schedule, both types of hepatitis A vaccine are safe and highly effective, importance of completing the full series for long-term protection, and at-risk groups including men who have sex with men.
6. U.S. Centers for Disease Control and Prevention. Genital herpes overview, including 2018 estimate of 572,000 new infections among people aged 14 to 49.
7. U.S. Centers for Disease Control and Prevention. PrEP information: about 99% reduction in risk of getting HIV from sex when taken as prescribed.
8. U.S. Centers for Disease Control and Prevention. HIV testing page: antibody-test window of 23 to 90 days and lab antigen/antibody-test window of 18 to 45 days after exposure.
9. U.S. Centers for Disease Control and Prevention. STI statistics landing page; hub for the annual STI surveillance reports that publish chlamydia, gonorrhea, and syphilis case counts for the United States.
10. World Health Organization. Human papillomavirus and cervical cancer fact sheet, including the approximately 76% of cervical cancers attributable to HPV types 16 and 18 globally.
11. World Health Organization. Herpes simplex virus fact sheet: global HSV-1 prevalence (about two-thirds under age 50) and HSV-2 prevalence (about 13% ages 15 to 49).
12. Corey L. et al. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. New England Journal of Medicine, 2004 (PubMed record): landmark placebo-controlled trial in heterosexual discordant couples showing ~48% reduction in HSV-2 acquisition (1.9% vs 3.6% placebo) on once-daily valacyclovir.

Sam Harper

Sam covers at-home sexual-health testing, public-health guidance, and clinical-testing basics for general audiences. Has been writing about consumer health since 2019, with a focus on translating CDC and WHO guidance into plain-English action items. Not a clinician; articles are summaries, not advice.